CORRECTION | Genetics inMedicine

Open

Correction: Initial experience from a renal genetics clinic demonstrates a distinct role in patient management

Christie P. Thomas, MBBS, Margaret E. Freese, MS, CGC, Agnes Ounda, MD, Jennifer G. Jetton, MD, Myrl Holida, PA-C, Lama Noureddine, MD and Richard J. Smith, MD

Genetics in Medicine (2021) 23:2017–2019; https://doi.org/10.1038/s41436-020-01000-0

Correction to: *Genetics in Medicine* **22**:2020; https://doi.org/10.1038/s41436-020-0772-y; published online 17 March 2020

The original PDF version of this Article contained an error in Table **3**. For subject number 74, the column labeled "Genetic testing" should read *CFI* p.Tyr369Ser, not *CFI* p.Tyr200Ser. This has now been corrected in both the PDF and HTML versions of the Article.

Published online: 6 October 2020

Table 3 Patients with a known genetic disease referred to the clinic for disease management ($n = 19$).

Subject number	Sex/age/ethnicity	FH	Diagnosis	Basis for diagnosis	Genetic testing	Testing lab	ACMG criteria	Reason for referral
1	F/50/EUR	Yes—multiple	Fabry disease	Low α-GAL A; positive family history	*GLA* p.Arg227Gln	Mount Sinai, New York, NY	LP: PM1, PM2, PP2, PP3, PP5	Renal biopsy
4–1	F/56/EUR	Yes—multiple	ADPKD	Cystic kidneys, positive family history		IIHG (Kidneyseq™), Iowa City, IA		CKD f/u
6	M/21/EUR	Yes—multiple	Fabry disease	Low α-GAL A; positive family history	*GLA* p.Ser297Tyr	Mount Sinai, New York, NY	LP: PM1, PM2, PM5, PP2, PP3	CKD f/u
7	M/29/EUR	No	Cystinosis	Fanconi syndrome, renal rickets and corneal crystals in infancy		Not done		Cysteamine Rx, manage disease
8	F/59/EUR	Yes—multiple	Fabry disease	Slit lamp, positive family history	*GLA* p.Trp204Ter	Mount Sinai, New York, NY	P: PVS1, PM1, PM2, PP3	CKD f/u
9	M/54/AFR	Yes—multiple	Fabry disease	Low α-GAL A; positive family history	*GLA* p.Trp340Ter	Mount Sinai, New York, NY	P: PVS1, PM1, PM2, PP3	CKD f/u
10	M/47/EUR	Yes—multiple	Fabry disease	Low α-GAL A; positive family history	*GLA* p.Ala29GlyfsTer2	Mount Sinai, New York, NY	P; PVS1, PM1, PM2, PP3	CKD f/u
11	F/27/EUR	Yes—sister	Cystinosis	Bone marrow biopsy positive for cystine crystals		Not done		Cysteamine Rx
19	F/23/EUR	No	Tuberous sclerosis	Clinical criteria		Not done		Manage renal AMLs
26	F/32/EUR	No	Tuberous sclerosis + TMA in pregnancy	TSC: clinical criteria	*TSC* 1c.1029 +3A>G; PLG p.Thr200Ala	CHG, Cambridge, MA; MORL (Genetic Renal Panel), Iowa City, IA	VUS: PM2, PP3, PP5; VUS: PP3	Manage tuberous sclerosis
27	M/18/EUR	Yes—multiple	Fabry disease	Kidney biopsy	*GLA* p.Cys63Arg	Mount Sinai, New York, NY	LP: PM1, PM2, PM5, PP2, PP3	CKD f/u
28	M/34/EUR	No	Fabry disease	Symptoms; positive family history	*GLA* p.Gly260Glu	Mount Sinai, New York, NY	LP: PM1, PM2, PM5, PP2, PP3	CKD f/u
31	M/24/EUR	No	Unilateral renal aplasia	Antenatal and postnatal imaging		Not done		CAKUT f/u
37	M/59/EUR	Yes—multiple	Suspected Fabry, no manifestation	Low α-GAL A; positive family history	*GLA* p.Ala143Thr	Mount Sinai, New York, NY	LP: PM1, PM5, PP2, PP3, PP5	Referred for renal biopsy
62	F/79/EUR	Yes—multiple	Familial hypocalciuric hypercalcemia	Hypercalcemia, positive family history	*CaSR* p.Pro55Leu	Mayo Medical Lab, Rochester, MN	LP: PM1, PM2, PP2, PP3, PP4, PP5	Post-test genetic counseling
66	F/34/EUR		aHUS			4		aHUS post-transplant f/u

Table 1 continued

Subject number	Sex/age/ethnicity	FH	Diagnosis	Basis for diagnosis	Genetic testing	Testing lab	ACMG criteria	Reason for referral
		Yes—sister		TMA, genetic screening	*CFH* p.Leu1189Argfs*2		P: PVS1, PM2, PP3	
67	M/30/EUR	No	None	Asymptomatic	Negative for *NPHP1* variant	IIHG (Kidneyseq™), Iowa City, IA		Preconception-counseling, spouse with *NPHP1* deletion
74	F/40/EUR	No	aHUS	TMA, genetic screening	*CFI* p.Tyr369Ser	MORL (Genetic Renal Panel), Iowa City, IA	LP: PM1, PM2, PP3, PP5	aHUS post-transplant f/u
75	F/38/EUR	No	aHUS	TMA, genetic screening	*CFH* p.Glu625Ter	MORL (Genetic Renal Panel), Iowa City, IA	P: PVS1, PM2, PP3	aHUS post-transplant f/u

Genetic screening in these patients was performed prior to referral.
ACMG American College of Medical Genetics and Genomics, *ADPKD* autosomal dominant polycystic kidney disease, *AFR* African/African American, *aHUS* atypical hemolytic uremic syndrome, *AML* angiomyolipoma, *CAKUT* congenital anomalies of kidney and urinary tract, *CHG* Center for Human Genetics, *CKD* chronic kidney disease, *EUR* Caucasian, *f/u* follow up, *FH* family history, *IIHG* Iowa Institute of Human Genetics, *LP* likely pathogenic, *MORL* Molecular Otolaryngology and Renal Research Laboratories, *P* pathogenic, *TMA* thrombotic microangiopathy, *TSC* tuberous sclerosis, *VUR* vesicoureteric reflux, *VUS* variant of unknown significance, *α-GAL A* α-galactosidase A.